Diabetes Control and Complication Trials

The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl I Med 1993 329 977-986. 

MCE, American Association of Clinical Endocrinologists ACE, American College of Endocrinology ADA, American Diabetes Association DCCT, Diabetes Control and Complications Trial. 

The Diabetes Control and Complications Trial (DCCT), the Stockholm Diabetes Intervention Study (DIS), the United Kingdom Prospective Diabetes Study (UKPDS), and the Japanese Kumamoto study show unequivocally that vigorous treatment of diabetes can decrease both the morbidity and mortality of the disease by reducing chronic complications. 

Diabetes Control and Complications Trial Research Group Epidemiology of severe hypoglycemia in the diabetes control and complications trial. Am J Med 1991 90 450. 

Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus. N Engl 3 Med 2003 348 2294. 

The most frequent complication of insulin therapy is inadvertent hypoglycemia (21-23). Over 5% of deaths in diabetes can be attributed to hypoglycemia. The frequency increases with rigorous maintenance of normogly-cemia (24,25). In the Diabetes Control and Complications Trial (DCCT) (26) the frequency of serious hypoglycemia was more than three times increased in the intensively treated group, and the frequency of the attacks was related to the concentration of HbAlc (27). The UK Prospective Diabetes Study in patients with type 2 diabetes also showed an increased risk of hypoglycemia with more intensive treatment (28). 

Austin EJ, Deary IJ. Effects of repeated hypoglycemia on cognitive function a psychometrically validated reanalysis of the Diabetes Control and Complications Trial data. Diabetes Care 1999 22(8) 1273-7. 

The Diabetes Control and Complications Trial Research Group. Influence of intensive diabetes treatment on body weight and composition of adults with type 1 diabetes in the Diabetes Control and Complications Trial. Diabetes Care 2001 24(10) 1711-21. 

Wagner VM, Grabert M, Holl RW. Severe hypoglcycemia, metabolic control and diabetes management in children with type 1 diabetes in the decade after the diabetes control and complications trial - a large scale multicentre study. Eur J Pediatr 2005 164 73-9. 

A long-term randomized prospective study involving 1441 type 1 patients in 29 medical centers reported in 1993 that "near normalization" of blood glucose resulted in a delay in onset and a major slowing of progression of microvascular and neuropathic complications of diabetes during followup periods of up to 10 years (Diabetes Control and Complications Trial [DCCT] Research Group,... 

The National Glycohemoglobin Standardization Program (NGSP) used the CRMLN model to establish a reference laboratory network to standardize glycated hemoglobin (i.e., HbAlc) [33, 34], The purpose of the NGSP is to standardize HbAlc so that clinical laboratory results are comparable to the Diabetes Control and Complications Trial (DCCT) where relationships were established to mean blood glucose and risk for vascular complications. 

The Diabetes Control and Complications Trial (DCCT) has shown that intensified diabetes therapy resulted in HbAlc reductions of approximately 2% compared to conventional therapy, and that patients practicing intensified diabetes therapy enjoyed significant reductions in the feared microvascular complications of diabetes (DCCT Research Group, 1993). As such, the current aim of diabetes therapy is to achieve glycemic control that is as close to normal as possible while maintaining an acceptable quality of life for those patients for whom the therapy is prescribed.The DCCT also demon-... 

The Diabetes Control and Complications Trial (DCCT) Group (1994) demonstrated that tight control and management of blood glucose levels decreases the risks of complications both in terms of microvascular (retinopathy and renal failure) and macrovascular (stroke, angina, myocardial infarction) complications. 

Danesh J, Whincup P, Walker M et al. (2000). Chlamydia pneumoniae IgG litres and coronary heart disease prospective study and metaanalysis. British Medical Journal 321 208-213 Danesh J, Whincup P, Walker M (2003). Chlamydia pneumoniae IgA litres and coronary heart disease prospective study and meta-analysis. European Heart Journal 24 881 Danesh J, Lewington S, Thompson SG et al. (2005). Plasma fibrinogen level and the risk of major cardiovascular diseases and non-vascular mortality an individual participant meta-analysis. Journal of American Medical Association 294 1799-1809 Diabetes Control and Complications Trial/ Epidemiology of Diabetes Interventions and Complications Research Group (2003). 

Diabetes Control and Complication Trial Research Group (1993). N. Engl. J. Med. 329, 977-986. 

---